Agios Appoints Richa Poddar as Chief Commercial Officer
“During her more than five-year tenure at Agios, Richa has played a significant leadership role in shaping our oncology portfolio and leading our oncology launch and marketing efforts, making her the ideal person to take the reins as we prepare for the launch of mitapivat in pyruvate kinase deficiency and continue to advance our genetically defined disease commercial strategy,” said
“I would also like to thank Darrin for his meaningful contributions to Agios, including his foundational work building and transforming our commercial capabilities, positioning us well for our first genetically defined disease product launch, and his leadership in commercial and program management roles supporting the development, approval and commercialization of two precision oncology medications,” continued
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. The company’s most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to its active late-stage clinical pipeline, Agios has multiple novel, investigational therapies in clinical and preclinical development. For more information, please visit the company’s website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefits of Ms. Poddar’s appointment and Agios’ strategic plans and focus. The words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, the FDA’s acceptance of Agios’s NDA for mitapivat does not represent evaluation of the efficacy and safety of mitapivat, and is not a guarantee of approval. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: risks associated with the regulatory review process generally; the risk that the FDA may determine that the data included in the NDA are insufficient for approval and that the Company must conduct additional clinical trials, or nonclinical or other studies, before mitapivat can be approved; the risk that the results of previously conducted studies involving mitapivat will not be repeated or observed in ongoing or future studies or following commercial launch, if mitapivat is approved; and risks associated with the Company’s dependence on third parties with respect to regulatory matters for mitapivat. These and other risks are described in greater detail under the caption “Risk Factors” included in Agios’ public filings with the Securities and Exchange Commission, or SEC. While the list of factors presented here is considered representative, this list should not be considered to be a complete statement of all potential risks and uncertainties. Any forward-looking statements contained in this communication are made only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect developments or information obtained after the date hereof and disclaim any obligation to do so other than as may be required by law.
Contacts
Investors:
Senior Director, Investor Relations
Holly.Manning@agios.com
Media:
Director, Corporate Communications
Jessica.Rennekamp@agios.com
Source: Agios Pharmaceuticals, Inc.